BOC RNA, a branch of BOC Sciences, is a custom lab chemical supply company, providing a wide range of services and products to support siRNA drug discovery mainly including oligo design/synthesis/purification/analysis, modification, in vivo delivery.
Home / Support / News
Vutrisiran, The World's Fourth RNAi Therapy, Is About to Submit A Marketing Application
From COVID-19 Vaccines to Anti-Cancer Drugs, What Is the Prospect of mRNA Therapy?
Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of
primary hyperoxaluria type 1 (PH1)
Breaking news: RNAi can significantly inhibit hepatitis B and is expected to become a new treatment for
Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot
Will the mRNA vaccine become the "savior" of COVID-19?
mRNA-1647□the first infectious disease mRNA vaccine to enter the second phase of research
FDA approves first RNAi treatment for inherited rare diseases
bioRxiv.: Scientists Find siRNA drugs that may inhibit SARS-CoV-2
Cell Immunity: SARS-CoV-2 vaccines status
Onpattro, The First FDA-approved RNAi Drug
SARS-CoV-2 is undergoing mutations. Does the vaccine still work?
* Only for research. Not suitable for any diagnostic or therapeutic use.
Call us at:
US & Canada (Toll free):
45-16 Ramsey Road, Shirley,
NY 11967, USA
2005 - 2021 BOC Sciences | All rights reserved